News | March 28, 2024
WuXi Biologics breaks ground on CRDMO Center in Singapore
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Hepatitis B infects over 40 million people in India
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
More than 10,000 scientific publications containing EUDRAGIT
Subscribe To Our Newsletter & Stay Updated
